BOSTON, Nov. 28, 2016 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference at 9:10 a.m. ET on Tuesday, November 29, 2016 in New York City.
Stealth BioTherapeutics: Leading Mitochondrial Medicine
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondrial therapies to patients to treat both rare and common diseases. Stealth's clinical development program is focused along several core therapeutic areas, including primary mitochondrial diseases, cardiorenal diseases and ophthalmic disorders. More information regarding Stealth and its pipeline is available at StealthBT.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-28th-annual-piper-jaffray-healthcare-conference-300368806.html
SOURCE Stealth BioTherapeutics